礼来两款产品纳入2025版国家基本医保目录，含替尔泊肽

Core Insights - The 2025 National Basic Medical Insurance Drug List and the first version of the Commercial Insurance Innovative Drug List were released in Guangzhou on December 7 [1] - Eli Lilly's two products were included in the basic medical insurance list, with a focus on the GLP-1/GIP drug Tirzepatide for type 2 diabetes treatment [1] Financial Performance - Tirzepatide's global sales for Q3 reached $6.515 billion, representing a year-on-year increase of 109% [1] - The total sales for the first three quarters amounted to $15.556 billion, showing a year-on-year growth of 94% [1]